Evidence map›Paper›PMID 34454651›Full record

ArticleThe Lancet. Oncology2021

Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study.

Sheena Mukkada, Nickhill Bhakta, Guillermo L Chantada, Yichen Chen, Yuvanesh Vedaraju, Lane Faughnan, Maysam R Homsi, Hilmarie Muniz-Talavera, Radhikesh Ranadive, Monika Metzger and 15 more

Open access · bronzeAbstract read
In one paragraph

Article in The Lancet. Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 6 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 6 syntheses or guidelines pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis.Journal of the Pediatric Infectious Diseases Society · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Clinical Outcomes of Pediatric Cancer Patients with COVID-19: A Cross-Sectional Study.International journal of hematology-oncology and stem cell research · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Pediatric cancer patients vaccinated against SARS-CoV-2-a clinical and laboratory follow-up.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  18. Article
  19. Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis.medRxiv : the preprint server for health sciences · 2024
    Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 9 institutions in 7 countries.

Sheena MukkadaDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: sheena.mukkada@stjude.org.
Nickhill BhaktaDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Guillermo L ChantadaDepartment of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.
Yichen ChenDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Yuvanesh VedarajuDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Lane FaughnanDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Maysam R HomsiDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Hilmarie Muniz-TalaveraDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Radhikesh RanadiveDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Monika MetzgerDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Paola FriedrichDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Asya AgulnikDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Sima JehaDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Catherine LamDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Rashmi DalviDepartment of Pediatrics, Bombay Hospital Institute of Medical Sciences, Mumbai, India.
Laila HessissenDepartment of Pediatric Hematology and Oncology, Mohammed V University, Rabat, Morocco.
Daniel C MoreiraDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Victor M SantanaDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Michael SullivanChildren's Cancer Centre, Royal Children's Hospital, Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia.
Eric BouffetDivision of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Miguela A CanizaDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Meenakshi DevidasDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Kathy Pritchard-JonesDevelopmental Biology and Cancer Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, London, UK.
Carlos Rodriguez-GalindoDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
Global Registry of COVID-19 in Childhood Cancer
St. Jude Children's Research Hospital · USBombay Hospital · INGreat Ormond Street Hospital · GBHospital Sant Joan de Déu Barcelona · ESUniversity College London · GBHospital for Sick Children · CAMohammed V University · MARoyal Children's Hospital · AUUniversity of Melbourne · AU

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
NCI NIH HHS P30 CA021765
6 · The paper itself

Abstract

backgroundPrevious studies have shown that children and adolescents with COVID-19 generally have mild disease. Children and adolescents with cancer, however, can have severe disease when infected with respiratory viruses. In this study, we aimed to understand the clinical course and outcomes of SARS-CoV-2 infection in children and adolescents with cancer.

methodsWe did a cohort study with data from 131 institutions in 45 countries. We created the Global Registry of COVID-19 in Childhood Cancer to capture de-identified data pertaining to laboratory-confirmed SARS-CoV-2 infections in children and adolescents (<19 years) with cancer or having received a haematopoietic stem-cell transplantation. There were no centre-specific exclusion criteria. The registry was disseminated through professional networks through email and conferences and health-care providers were invited to submit all qualifying cases. Data for demographics, oncological diagnosis, clinical course, and cancer therapy details were collected. Primary outcomes were disease severity and modification to cancer-directed therapy. The registry remains open to data collection.

findingsOf 1520 submitted episodes, 1500 patients were included in the study between April 15, 2020, and Feb 1, 2021. 1319 patients had complete 30-day follow-up. 259 (19·9%) of 1301 patients had a severe or critical infection, and 50 (3·8%) of 1319 died with the cause attributed to COVID-19 infection. Modifications to cancer-directed therapy occurred in 609 (55·8%) of 1092 patients receiving active oncological treatment. Multivariable analysis revealed several factors associated with severe or critical illness, including World Bank low-income or lower-middle-income (odds ratio [OR] 5·8 [95% CI 3·8-8·8]; p<0·0001) and upper-middle-income (1·6 [1·2-2·2]; p=0·0024) country status; age 15-18 years (1·6 [1·1-2·2]; p=0·013); absolute lymphocyte count of 300 or less cells per mm

interpretationIn this global cohort of children and adolescents with cancer and COVID-19, severe and critical illness occurred in one fifth of patients and deaths occurred in a higher proportion than is reported in the literature in the general paediatric population. Additionally, we found that variables associated with treatment modification were not the same as those associated with greater disease severity. These data could inform clinical practice guidelines and raise awareness globally that children and adolescents with cancer are at high-risk of developing severe COVID-19 illness.

fundingAmerican Lebanese Syrian Associated Charities and the National Cancer Institute.

Indexed as

COVID-19NeoplasmsAdolescentChildChild, PreschoolCohort StudiesFemaleHumansInfantInfant, NewbornMaleRisk FactorsSARS-CoV-2Severity of Illness Index

Identifiers

PMID34454651
PMCPMC8389979
OpenAlexW3196277563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.